Test Gains Medicare Coverage for Early-Stage Breast Cancer Recurrence Monitoring
Coverage marks a step in expanding access to ultra-sensitive molecular residual disease detection for breast cancer patients.
Category: Breast
Breast
Latest
Breast
Latest
AI-Powered Blood Test Spots Earliest Sign of Breast Cancer
A new laser analysis and AI method capable of detecting stage 1a breast cancer with 98% accuracy offers an effective screening option.
Breast
Latest
UCLA and PreciseDx Collaborate on AI-Powered Breast Cancer Recurrence Diagnostics
This collaborative study seeks to represent a significant step forward in digital pathology and oncology breast cancer research
Weill Cornell Medicine Gets Grant for Breast Cancer Liquid Biopsy
A new test uses AI to see whether a patient is positive for cancer as soon as detectable by mammogram or earlier, and before symptoms arise.
Read More
Male Breast Cancer Diagnosis Leads to New Treatment Approach
Though breast cancer rates for men are much lower, it is estimated that in 2023, about 2,800 men will be diagnosed with breast cancer.
Read More
Exai Bio’s RNA-Based Liquid Biopsy Platform Detects Early Stage Breast Cancer Accurately
Exai Bio’s liquid biopsy platform can detect breast cancer at the earliest stages and the smallest tumor sizes using a standard blood sample.Â
Read More
Reveal Genomics Details Success of Liquid Biopsy Test for Metastatic Breast Cancer
DNADX utilizes sequencing DNA data from tumor tissue or plasma circulating tumor DNA to classify breast cancer into four subtypes or clusters.
Read More
Digital Morphology Solution Predicts Breast Cancer Recurrence
PreciseBreast, an AI-powered digital morphology tool, has a fast turnaround time and is cost-effective compared to gene expression tests.
Read More
Universal Hereditary Cancer Genetic Testing Breast Cancer Improves Patient Outcomes
Invitae announced the results of its study on universal hereditary cancer genetic testing in breast cancer patients in a rural population.
Read More
Biocartis Expands APIS Assay Technologies Collab to Commercialize Mutations Kit
Biocartis and APIS Assay Technologies are expanding their collaboration to include the commercialization of the APIS ESR1 Mutations Kit.
Read More
Study Finds Reductions in Breast Cancer Screening During Pandemic
The findings suggest the need for continued monitoring of access to breast cancer screening and early diagnosis services.
Read More
Ibex Launches Galen Breast HER2 to Support Breast Cancer Biomarker Scoring
Ibex launched an AI-powered solution that aids pathologists in setting a higher standard for accurate HER2 scoring in breast cancer patients.
Read More
How a Computational Model Predicts Genetic Risk for Breast Cancer
This computational model makes it possible to predict the genetic risk of developing breast cancer based on genetic profiles.Â
Read More
Breast Cancer Overdiagnosis Common Among Older Women
New findings suggest that overdiagnosis may be common among older women who are diagnosed with breast cancer after screening.
Read More
Devyser Debuts 2 Genetic Test Kits for Hereditary Cancer
Devyser LynchFAP and Devyser BRCA PALB2 genetic test kits offer efficient, targeted analysis of genes associated with increased cancer risk.
Read More
Exai Bio Expands RNA-based Breast Cancer Liquid Biopsy Platform through Collaboration
Exai Bio is collaborating with Quantum Leap Healthcare Collaborative to broaden the use of its novel, RNA-based liquid biopsy platform.
Read More
DCIS Risk Assessment Test Gets CMS Advanced Diagnostic Laboratory Test Status Approval
The Centers for Medicare & Medicaid Services approved Advanced Diagnostic Laboratory Test status for PreludeDx’s DCISionRT test.
Read More
Medicare Extends Coverage of Natera’s Signatera MRD Test to Breast Cancer
Natera’s Signatera MRD test has met coverage requirements for adjuvant and recurrence monitoring in patients with breast cancer.
Read More